Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Normoxia Sverige AB
AB
Active
Org 5593808461
Bergs Säteri 1
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2022
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 312K
+100% vs 2024
EBITDA margin
85.6%
+138% vs 2024
Equity ratio
84.1%
Financial strength
Net profit 2025
SEK 214K
+141% vs 2024
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
SEK 312K
+100%
EBITDA
SEK 267K
+138%
Net profit
SEK 214K
+141%
Total assets
SEK 302K
+24%
Equity
SEK 254K
+21%
Employees
0
—
Company information
Legal name
Normoxia Sverige AB
Org number
5593808461
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 maj 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva verksamhet inom medicinsk forskning och inom hälso- och sjukvård samt därmed förenlig verksamhet.
Contact
Address
Bergs Säteri 1
Email
bernhard.holzgraefe@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Arvika
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2023
2024
2025
Revenue
129
156
312
Staff expenses
—
−1
−9
EBITDA
121
112
267
Depreciation & amort.
—
—
—
EBIT
121
112
267
Net financials
−0
1
4
Profit before tax
120
113
271
Tax
−25
−24
−56
Net profit
96
89
214
Balance sheet
SEK thousands
Item
2023
2024
2025
Total assets
129
244
302
Equity
121
210
254
Long-term debt
—
—
—
Short-term debt
8
34
48
Total debt
8
34
48
Financial ratios
5-year trend
EBITDA margin
85.6%
This company
15.8%
Market median
+442% vs market
2023
2025
Equity ratio
84.1%
This company
38.2%
Market median
+120% vs market
2023
2025
Return on equity
84.4%
This company
18.4%
Market median
+359% vs market
2023
2025
Net profit margin
68.7%
This company
8.1%
Market median
+748% vs market
2023
2025
Asset turnover
1.03×
This company
1.12×
Market median
+8% vs market
2023
2025
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
2023
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-05-14 – 2023-05-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
BH
Bernhard Holzgraefe
Board of Directors
2022
EL
Elisa Lou Isolde von Kobyletzki
Deputy Board Member
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Normoxia Sverige AB also hold positions in
0
other companies.
Person
Role here
Other companies
Bernhard Holzgraefe
Board of Directors
0 companies
Elisa Lou Isolde von Kobyletzki
Deputy Board Member
0 companies